Antibody-Mediated Tumor Killing

Antibody-mediated tumor killing refers to the process by which antibodies, specifically monoclonal antibodies, play a crucial role in targeting and eliminating cancer cells. This mechanism involves the use of engineered antibodies that are designed to recognize and bind to specific antigens expressed on the surface of tumor cells. Once bound, these antibodies can initiate various immune responses to eliminate the cancer cells.

There are several mechanisms involved in antibody-mediated tumor killing, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP).

Figure 1. Antibody-Mediated Tumor Killing

Application

1. Immunotherapy assessment: These assays are used to evaluate the efficacy of immunotherapeutic strategies, such as monoclonal antibody therapies, by measuring the ability of immune cells to kill target cells or pathogens.
2. Antibody characterization: ADCC and ADCP assays are employed to determine the potency and functionality of antibodies by assessing their ability to engage immune cells and induce cell killing or phagocytosis.
3. Cancer immunology: These assays are used to study the role of immune cells in tumor microenvironments and evaluate the potential of immune cell-mediated cytotoxicity in tumor clearance. They can help identify potential therapeutic targets and develop personalized cancer treatments.
4. Vaccine development: ADCC and ADCP assays play a crucial role in assessing the immune response to vaccines by measuring the ability of vaccine-induced antibodies to mediate the killing or phagocytosis of target cells or pathogens.
5. Drug discovery: ADCC, CDC, and ADCP assays are used in drug screening to assess the cytotoxic effects of potential drug candidates. These assays can help identify compounds that induce immune cell-mediated killing and phagocytosis, which may be relevant in the treatment of various diseases.

Creative Bioarray's ADCC, CDC, and ADCP assays provide valuable tools for evaluating the tumor-killing potential of therapeutic antibodies. By providing quantitative and qualitative data on the tumor-killing mechanisms employed by therapeutic antibodies, these assays enable researchers and developers to evaluate antibody efficacy, select optimal candidates for further development, and monitor therapeutic antibody performance during preclinical and clinical stages. Ultimately, they contribute to the advancement of targeted cancer therapies by optimizing the design and development of effective antibody-based treatments.

Antibody-Dependent Cellular Cytotoxicity (ADCC)

Complement-Dependent Cytotoxicity (CDC)

Antibody-dependent Cellular Phagocytosis (ADCP)